3 assets in Combined Hepatocellular Carcinoma And Cholangiocarcinoma

Therapeutic assets addressing Combined Hepatocellular Carcinoma And Cholangiocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Combined Hepatocellular Carcinoma And Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Capecitabine Combined Hepatocellular Carcinoma And Cholangiocarcinoma	Shanghai Zhongshan Hospital	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Combined Hepatocellular Carcinoma And Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)